Physician profile
Sachin Mehta
NPI 1295926194
$645,928.22
in general payments reported to CMS, 2019-2025
30 companies · $307K in 2025
The $307K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,223 · 2020: $976 · 2021: $1,633 · 2022: $34K · 2023: $115K · 2024: $178K · 2025: $307K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $440K · Travel and Lodging: $55K · Honoraria: $43K · Consulting Fee: $39K · Food and Beverage: $23K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $440,016.01 |
| Travel and Lodging | $54,757.78 |
| Honoraria | $42,762.50 |
| Consulting Fee | $39,451.00 |
| Food and Beverage | $22,825.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176,187.17 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $135,411.49 | 2024-2025 | Cobenfy |
| Abbvie INC. | $120,816.49 | 2021-2025 | |
| Alkermes, INC. | $70,462.45 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $64,563.81 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $37,769.60 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $24,382.19 | 2022-2023 | Quviviq |
| Corium, LLC | $8,701.37 | 2022-2025 | Azstarys, Azstarys |
| Biogen, INC. | $1,568.61 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $1,089.28 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $795.50 | 2019-2025 | Trintellix |
| Allergan, INC. | $623.19 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $568.10 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $429.03 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $376.07 | 2019-2025 | Ingrezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $368.73 | 2019-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $351.74 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $349.75 | 2023-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $346.74 | 2019-2022 | |
| Neos Therapeutics, Lp | $173.39 | 2022-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $126.80 | 2019-2024 | Aplenzin |
| Tris Pharma INC | $107.38 | 2023-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $86.41 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $64.97 | 2022-2023 | Loreev Xr |
| Indivior INC. | $60.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $49.56 | 2019 | |
| Neuronetics, INC. | $30.54 | 2022-2023 | Neurostar Tms Therapy System |
| Tempus Ai, INC | $28.33 | 2024 | |
| Owp Pharmaceuticals, INC. | $21.07 | 2022 | |
| Genentech USA, INC. | $18.04 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.